In addition, we screened four potential small-molecule compounds for GC, including AZD6482 (PI3K inhibitor), BX.795 (TBK1 inhibitor), GDC0941 (dual PI3K and mTOR inhibitor), and pazopanib (tyrosine kinase inhibitor). This evidence concerns the gene MTOR and gastric cancer.